{Reference Type}: Journal Article
{Title}: [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
{Author}: Melicine S;Maucorps L;Eschwège V;Carré J;Helley D;Gouin-Thibault I;Gendron N;Nédélec-Gac F;Mauge L;
{Journal}: Ann Biol Clin (Paris)
{Volume}: 82
{Issue}: 2
{Year}: 2024 06 5
{Factor}: 0.516
{DOI}: 10.1684/abc.2024.1873
{Abstract}: Contrary to direct oral anticoagulants (DOAC), unfractionated heparin (UFH) requires daily monitoring when administered at therapeutic dose. At present, UFH monitoring is preferably carried out by measuring plasma anti-Xa activity, however, in patients previously treated with an anti-Xa DOAC and switched to UFH, there is a high risk of DOAC interfering with the measurement of UFH anti-Xa activity. Residual anti-Xa DOAC in the sample can lead to an overestimation of the anticoagulant activity attributed to heparin and thus to incorrect anticoagulation. This risk of interference should not be overlooked because interference may occur even at concentration of DOAC below the hemostatic safety threshold and can last several days. To overcome this issue, several alternatives are being studied. This note provides an update on anti-Xa DOAC interference and different strategies available in current practice. It also underlines the importance of communication between biologists and clinicians on anticoagulant treatments received by patients.